



Relpax[®] (eletriptan) – First-time generic

- On July 25, 2017, generic versions of Pfizer's [Relpax \(eletriptan\)](#) 20 mg and 40 mg tablets were launched.
 - [Teva launched](#) an [AB-rated](#) generic version of Relpax.
 - [Greenstone launched](#) an authorized generic version of Relpax.
 - In addition, Zydus received [FDA approval](#) of an [AB-rated](#) generic version of Relpax. Launch plans are pending for this product.
- Relpax is a serotonin (5-HT_{1B/1D}) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults.
 - Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with Relpax, reconsider the diagnosis of migraine before Relpax is administered to treat any subsequent attacks.
 - Relpax is not intended for the prevention of migraine attacks.
 - Safety and effectiveness of Relpax have not been established for cluster headache.
- Other generic triptans are available: [almotriptan](#), [frovatriptan](#), [naratriptan](#), [rizatriptan](#), and [sumatriptan](#).



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.